Can an ancient herbal remedy boost IVF pregnancy rates?
NCT ID NCT07347340
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial tests whether a traditional Chinese herbal formula, Bushen Tongzhi, can improve pregnancy rates in women with diminished ovarian reserve who are undergoing IVF. About 348 women aged 22-39 will take either the herbal granules or a placebo three times daily for up to 6 months before and during their IVF cycle. The study aims to see if the herbal pretreatment leads to more clinical pregnancies compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Bushen Tongzhi Formula (a traditional Chinese herbal granule)
- What this could lead to
- If it works, this could offer a safe, low-cost pretreatment to improve IVF success for women with diminished ovarian reserve.
- What could go wrong
- This is a phase 3 trial, but herbal remedies often show mixed results in rigorous testing. The benefit may be small or no better than placebo, and individual responses can vary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 348 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
22 to 39 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women aged 22 to 39 years (inclusive). * Diagnosis of diminished ovarian reserve (DOR), defined by meeting at least two of the following three criteria: 1, Basal follicle-stimulating hormone (FSH) level between 10 and 25 IU/L (measured on menstrual cycle days 2-4); 2, Anti-Müllerian hormone (AMH) level \< 1.1 ng/mL; 3, Antral follicle count (AFC) \< 7 (total count of follicles 2-10 mm in diameter in both ovaries). * Diagnosis of infertility, defined as failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse. * Diagnosis of Kidney Deficiency pattern according to Traditional Chinese Medicine criteria, as defined in the study protocol. * Scheduled to undergo a fresh in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycle. * Willing and able to provide written informed consent. Exclusion Criteria: * Uterine structural abnormalities likely to impair implantation or pregnancy (e.g., untreated submucosal fibroids, severe intrauterine adhesions, uterine septum). * Known abnormal karyotype in either partner. * Uncontrolled or severe medical conditions (e.g., hypertension, diabetes, thyroid dysfunction, hepatic/renal insufficiency, symptomatic heart disease). * Diagnosed severe psychiatric disorders (e.g., schizophrenia, bipolar disorder). * History of prior pelvic radiation or cytotoxic chemotherapy. * Active genital tract infection. * Diagnosed or suspected severe (ASRM stage III-IV) endometriosis with recurrent symptoms. * Planned use of donor oocytes or preimplantation genetic testing (PGT). * History of repeated IVF/ICSI failure (≥3 failed egg retrieval cycles or ≥3 failed transfers of high-quality embryos). * Known allergy to any component of the investigational herbal formula. * Participation in another clinical trial within the past 3 months. * Use of medications known to affect ovarian function (e.g., DHEA, growth hormone) within the past month. * Current heavy alcohol consumption or smoking. * Any other condition deemed by the investigator to make the participant unsuitable for the study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diminished ovarian reserve (DOR) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tiny electric acupuncture needles help women with low egg reserve conceive?
- Ancient herbal formula put to the test for boosting egg maturity
- Ancient herbal recipe put to the test for waning fertility
- Ovarian puncture may boost egg count in women with low reserve
- Herbal hope: TCM trial targets fertility in women with low egg reserve
- Stem cell shot into ovaries aims to tame perimenopause symptoms